

ABSTRACT OF THE INVENTION

The present invention encompasses the use of a CD2 antagonist, preferably
MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent
5 therapy for the prevention, treatment, management, or amelioration of cancer, particularly a
T-cell malignancy, or one or more symptoms thereof. The present invention also
encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an
antigen-binding fragment thereof in combination with other cancer therapies. The present
invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably
10 MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts
effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy,
or one or more symptoms thereof.